Published in Radiother Oncol on August 10, 2007
Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation. Strahlenther Onkol (2009) 0.96
Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol (2013) 0.84
Impact of late anorectal dysfunction on quality of life after pelvic radiotherapy. Int J Colorectal Dis (2012) 0.84
Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian Centre. Cancers (Basel) (2011) 0.80
Reducing rectal injury during external beam radiotherapy for prostate cancer. Nat Rev Urol (2013) 0.80
Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer. Adv Urol (2011) 0.79
Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer. Toxicity, tumour response and outcome. Strahlenther Onkol (2012) 0.77
Chronic radiation proctitis: tricks to prevent and treat. Int J Colorectal Dis (2015) 0.76
ESUR prostate MR guidelines 2012. Eur Radiol (2012) 8.86
Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys (2006) 2.92
Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol (2009) 2.25
[18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol (2006) 2.22
An anatomically validated brachial plexus contouring method for intensity modulated radiation therapy planning. Int J Radiat Oncol Biol Phys (2013) 2.13
Population screening for prostate cancer: an overview of available studies and meta-analysis. Int J Urol (2011) 2.11
Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol (2008) 2.00
Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist (2007) 1.94
Accuracy of patient dose calculation for lung IMRT: A comparison of Monte Carlo, convolution/superposition, and pencil beam computations. Med Phys (2006) 1.66
Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer. Int J Radiat Oncol Biol Phys (2004) 1.50
Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.46
Lethal pneumonitis in a phase I study of chemotherapy and IMRT for NSCLC: the need to investigate the accuracy of dose computation. Radiother Oncol (2005) 1.44
Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancer. Prostate (2014) 1.41
Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int J Radiat Oncol Biol Phys (2010) 1.33
Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys (2009) 1.22
Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys (2008) 1.20
Soluble cadherins as cancer biomarkers. Clin Exp Metastasis (2007) 1.20
Dosimetric characterization of GafChromic EBT film and its implication on film dosimetry quality assurance. Phys Med Biol (2007) 1.18
Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol (2006) 1.16
Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys (2004) 1.16
Does ionizing radiation stimulate cancer invasion and metastasis? Bull Cancer (2008) 1.15
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol (2014) 1.14
Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer (2014) 1.13
Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy. BMC Cancer (2014) 1.13
Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients. Cancer (2005) 1.13
Analysis of prostate bed motion using daily cone-beam computed tomography during postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.13
Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer (2012) 1.11
Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.11
Prediction of late normal tissue complications in RT treated gynaecological cancer patients: potential of the gamma-H2AX foci assay and association with chromosomal radiosensitivity. Oncol Rep (2010) 1.10
Adaptive dose painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 1.08
Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys (2008) 1.07
IMRT treatment planning:- a comparative inter-system and inter-centre planning exercise of the ESTRO QUASIMODO group. Radiother Oncol (2005) 1.06
Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate (2014) 1.05
The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol (2005) 1.03
A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.02
Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. Radiother Oncol (2011) 1.02
Conversion of CT numbers into tissue parameters for Monte Carlo dose calculations: a multi-centre study. Phys Med Biol (2007) 1.02
Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. Radiother Oncol (2009) 1.01
High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol (2011) 1.01
Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial. Radiother Oncol (2013) 1.00
TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat Oncol Biol Phys (2006) 0.99
Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother Oncol (2008) 0.99
Predicting risk of radiation-induced lung injury. J Thorac Oncol (2007) 0.99
Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience. Int J Radiat Oncol Biol Phys (2003) 0.98
Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation. Strahlenther Onkol (2009) 0.96
DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res (2012) 0.96
Whole breast radiotherapy in prone and supine position: is there a place for multi-beam IMRT? Radiat Oncol (2013) 0.95
Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome. Radiother Oncol (2013) 0.95
No association between TGF-β1 polymorphisms and radiation-induced lung toxicity in a European cohort of lung cancer patients. Radiother Oncol (2012) 0.95
Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. Int J Radiat Oncol Biol Phys (2012) 0.94
Resident and bone marrow-derived mesenchymal stem cells in head and neck squamous cell carcinoma. Oral Oncol (2010) 0.93
Delineation of the postprostatectomy prostate bed using computed tomography: interobserver variability following the EORTC delineation guidelines. Int J Radiat Oncol Biol Phys (2011) 0.93
Radiotherapy and surgery-an indispensable duo in the treatment of retroperitoneal sarcoma. Cancer (2011) 0.93
Intensity modulating and other radiation therapy devices for dose painting. J Clin Oncol (2007) 0.92
Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. Radiother Oncol (2010) 0.92
IMRT for sinonasal tumors minimizes severe late ocular toxicity and preserves disease control and survival. Int J Radiat Oncol Biol Phys (2011) 0.92
Single-nucleotide polymorphisms in DNA double-strand break repair genes: association with head and neck cancer and interaction with tobacco use and alcohol consumption. Mutat Res (2008) 0.91
Hypofractionated whole breast irradiation for patients with large breasts: a randomized trial comparing prone and supine positions. Radiother Oncol (2013) 0.91
Lack of a correlation between γH2AX foci kinetics in lymphocytes and the severity of acute normal tissue reactions during IMRT treatment for head and neck cancer. Int J Radiat Biol (2011) 0.88
Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest Radiol (2011) 0.88
Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFβ1 gene. Int J Radiat Oncol Biol Phys (2012) 0.88
Three dimensional radiation dosimetry in lung-equivalent regions by use of a radiation sensitive gel foam: proof of principle. Med Phys (2006) 0.87
Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol (2009) 0.87
Evaluation of deformable image coregistration in adaptive dose painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2011) 0.87
Role of imaging in the diagnosis and management of complete androgen insensitivity syndrome in adults. Case Rep Radiol (2013) 0.86
Alternated prone and supine whole-breast irradiation using IMRT: setup precision, respiratory movement and treatment time. Int J Radiat Oncol Biol Phys (2011) 0.86
Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: a prospective report on toxicity. Int J Radiat Oncol Biol Phys (2012) 0.86
Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity. Radiother Oncol (2013) 0.86
Report of a study on IMRT planning strategies for ethmoid sinus cancer. Strahlenther Onkol (2002) 0.85
The use of magnetic sensors to monitor moderate deep inspiration breath hold during breast irradiation with dynamic MLC compensators. Radiother Oncol (2007) 0.85
Reliability and accuracy assessment of Radiation Therapy Oncology Group-endorsed guidelines for brachial plexus contouring. Strahlenther Onkol (2014) 0.85
Regional relapse after intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 0.84
Hypofractionated frameless stereotactic intensity-modulated radiotherapy with whole brain radiotherapy for the treatment of 1-3 brain metastases. Neurol Sci (2012) 0.84
Evaluation of the Sinmed Mastercouch as replacement for a standard couch. Radiother Oncol (2005) 0.84